Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

NCT00079326 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

39

Enrollment

NIH

Sponsor class

Stopped Slow accrual.

Conditions

HER2-positive Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions

BIOLOGICAL: trastuzumab
DRUG: ixabepilone
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)